Taher Modarressi, M.D.
@tmodarressi
Cardiometabolic medicine. Endocrinology, lipidology, obesity medicine. Via @PennMedicine and @MGHMedicine.
Out now in @AJPCardio! Managing high-risk pts w T2D+ASCVD in our specialized cardiometabolic clinic: high-volume implementation of GLP1RA/SGLT2i, and 89% achieved LDL-C levels below thresholds for intensification, incl <55mg/dL for pts at very-high risk doi.org/10.1016/j.ajpc…
Subclinical Primary Aldosteronism — any aldosterone produced when renin is low, even in normotensive people -- associated with incident MACE
Our new data on subclinical PA and MACE is out in Circulation! For the first time, we show that renin-independant aldosterone production is associated with an increased risk of MACE independently of BP, in people mostly normotensive with low CV risk. ahajournals.org/doi/full/10.11…
New Primary Aldosteronism Guidelines - simpler, streamlined, and hopefully more pragmatic. academic.oup.com/jcem/advance-a…
➡️In @LipidJournal: real-world data, early experience with inclisiran @UCSDHealth @UCSDCardiology Congrats @DMazdeyasnan, @AntoinetteBirs, @TommyTChiou @PamTaubMD @ASPCardio @CBallantyneMD @DrMichaelShapir @tmodarressi @ArchnaBajajMD @Nishant_ShahMD sciencedirect.com/science/articl…
BIG NEWS in the obicetrapib story - fiercebiotech.com/biotech/newams… Patients had significant reductions in the biomarker p-tau217 compared to their counterparts on placebo. The result was statistically significant in the full Alzheimer’s population and in the 367 ApoE4 carriers. Other…
Our new study on the AHA PREVENT Equations and Lp(a) is out now @JAMACardio @AlexRazavi @JSpitz_MD @jaideeppatelmd @DrMichaelShapir @Lpa_Doc @amehta_09 @UCSDCardiology @UCSDCardFellows @ASPCardio @FamilyHeartFdn #KnowLpa Key Points in the thread below:
The PREVENT equations effectively predict cardiovascular disease risk overall, including for individuals with elevated lipoprotein(a). ja.ma/4jRVM9P
Great framework for clinically differentiating FCS and MCS by @Dr_Zahid_Ahmad at #NLASessions.
🧪 New Phase 2 Trial: High-Dose Semaglutide (up to 16 mg/week) --- Can more sema drive more results in type 2 diabetes + obesity? Let’s break it down ⬇️ 🔍 STUDY DESIGN 🔹245 adults w/ type 2 diabetes + BMI ≥27 kg/m² 🔹All on metformin 🔹Randomized to: ◽ Semaglutide 2 mg…
Really enjoyed Max Petersen’s talk at #NLASessions on the topic of hypothetical mechanisms of increased LDL cholesterol and ApoB with ketogenic diets. Looking forward to his forthcoming data measuring metabolic fluxes! clinicaltrials.gov/study/NCT06894…
A particularly meaningful moment to see my great teacher and mentor, and the person who first sparked my interest in lipids, @dan_soffer receive the @nationallipid Clinician Educator Award at #NLASessions.
Phenomenally rich talk on FH by @DrSafarova at #NLASessions highlighting the phenotypic heterogeneity of LDLr pathogenic variants, updated prevalence data and range of yield with genetic testing.
And perhaps the most intriguing data presented by @KevinH_PhD at #NLASessions: Interim analysis from a fascinating trial suggests UPFs may not inherently drive weight gain; instead, it’s energy density and hyperpalatability of the UPFs that is associated with ad lib energy intake…
There has been an idea that ultra-processed foods merely induce an “addictive” effect due to dopamine release. That does not find support in a recent study. Presented by @KevinH_PhD at #NLASessions
Absolutely incredible talk from @KevinH_PhD. First key point: In the U.S., we have an extremely efficient agricultural system for producing calories. Interestingly, while total food supply has increased since the 1970s, two-thirds of those add’l calories now end up in the trash.
Absolutely incredible talk from @KevinH_PhD. First key point: In the U.S., we have an extremely efficient agricultural system for producing calories. Interestingly, while total food supply has increased since the 1970s, two-thirds of those add’l calories now end up in the trash.
Intriguing signal: patients receiving $NAMS obicetrapib showed a trend toward reduced new-onset diabetes, at #NLASessions
“Drop-in” use of other lipid-lowering therapies remains a key challenge in modern lipid trials. At #NLASessions, a poster on $ESPR CLEAR-Outcomes clarifies the extent of drop-in and suggests minimal impact on the primary outcome.
A nice list of currently ongoing trials looking at CCTA in primary prevention by @DineshKalra at #NLASessions
Change in nomenclature in the FH world to describe the HoFH phenotype? Interesting shift and should help with uptake of evinacumab. At #NLASessions
A very interesting way of visualizing the spectrum of HTG. By @smsaadatagah and presented by @CBallantyneMD at #NLASessions
